AsbaghiOSadeghianMMozaffari-KhosraviHMalekiVShokriAHajizadeh-SharafabadFet al
KAI-7535 is an oral small-molecule GLP-1 receptor agonist that demonstrated competitive weight loss efficacy in a Phase 2 clinical trial in China
Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional
Before recommending peptide therapy, our providers may evaluate: Your health goals Current symptoms Injury or recovery concerns Medical history Medication and supplement use Sleep, stress, and lifestyle factors Mental health history Hormonal or metabolic concerns Lab testing when appropriate Safety risks and contraindications If peptide therapy is appropriate, your provider will explain the recommended approach, possible benefits, limitations, risks, and follow-up plan
Eli Lilly showed a similar pattern